Search
Displaying 671–680 of 865 results for “vision connection”
-
Foundation Invests $2.5 Million in Search for Elusive Retinal Disease Genes and Mutations
Research NewsSince 1989 genetic researchers, many funded by the Foundation, have identified approximately 270 genes linked to IRDs. In most cases, defects in a single gene can cause a retinal disease and vision loss.
-
Apellis Launches Phase 3 Clinical Trial Program for Advanced Dry AMD Treatment
Research NewsTrial participants will receive intravitreal injections of APL-2, or a sham procedure (placebo), monthly or every other month. The injections are made into the vitreous, the soft gel in the middle of the eye.
-
Call to Action: Ask Congress to Support $1 Billion in Eye Research
Research NewsCall to Action: Ask Congress to Support $1 Billion in Eye Research
-
French Gene Therapy Company Advancing Three Programs for Retinal Diseases
Research NewsHorama’s gene therapies are injections of healthy copies of a gene underneath the retina to compensate for the defective gene.
-
ARVO 2018: Studies Show Mediterranean Diet May Lower Advanced AMD Risk
Research NewsSeveral research studies have suggested that the Mediterranean diet (MeDi) - which is rich in fruits, vegetables, legumes, cereals, and fish - may be good for your health, including lowering your risk of an early visit from the grim reaper.
-
Ophthotech Launching Human Study of Emerging Therapy for Stargardt Disease
Research NewsOphthotech, a biopharmaceutical company developing therapies for eye diseases, has enrolled the first patient in its Phase 2b clinical trial of Zimura® for people with Stargardt disease caused by mutations in the gene ABCA4.
-
ProQR Doses First Participant in Its LCA10 Therapy Clinical Trial
Research NewsThe company plans to report interim, six-month study results in 2018 and 12-month results in 2019.
-
Beacon Stories
Joe Caruso, founder of FOCUS Wine Foundation, knows life both with and without the ability to see. His first memory is sitting in the waiting room with his mother at the Scheie Eye Institute in Philadelphia.
-
Clinical Trial Authorized in the U.S. for Emerging LCA 10 Therapy
Research NewsProQR, a biotechnology company in the Netherlands, has received authorization from the U.S. Food and Drug Administration to start a Phase I/II clinical trial for its therapy known as QR-110
-
Nobel-Prize-Winning Stem-Cell Researcher Delivers Keynote at FFB-Funded Conference in Kyoto
Research NewsDr. Shinya Yamanka discussed his early clinical trial for iPSC-derived retinal pigment epithelial (RPE) cells for a 78-year-old woman with advanced wet age-related macular degeneration (AMD).
